Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NASDAQ | Common Stock
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company.
The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences.
It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.
In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body.
Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
On February 10, 2025, Omega Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the District of Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 15, 24 | -0.30 Increased by +25.00% | -0.27 Decreased by -10.42% |
| Aug 6, 24 | -0.30 Increased by +44.44% | -0.36 Increased by +16.67% |
| May 6, 24 | -0.36 Increased by +28.00% | -0.33 Decreased by -9.09% |
| Mar 28, 24 | -0.37 Increased by +42.19% | -0.45 Increased by +17.78% |
| Nov 9, 23 | -0.40 Increased by +25.93% | -0.53 Increased by +24.53% |
| Aug 3, 23 | -0.54 Increased by 0.00% | -0.51 Decreased by -5.88% |
| May 4, 23 | -0.50 Decreased by -19.05% | -0.60 Increased by +16.67% |
| Mar 1, 23 | -0.64 Decreased by -45.45% | -0.63 Decreased by -1.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 2.61 M Increased by +214.32% | -16.44 M Increased by +26.09% | Decreased by -629.56% Increased by +76.49% |
| Jun 30, 24 | 2.13 M Increased by +181.16% | -16.30 M Increased by +45.08% | Decreased by -764.06% Increased by +80.47% |
| Mar 31, 24 | 2.36 M Increased by +357.36% | -20.13 M Increased by +16.33% | Decreased by -852.92% Increased by +81.71% |
| Dec 31, 23 | 989.00 K Increased by +34.56% | -20.21 M Increased by +34.12% | Decreased by -2.04 K% Increased by +51.04% |
| Sep 30, 23 | 831.00 K Increased by +39.66% | -22.25 M Increased by +13.14% | Decreased by -2.68 K% Increased by +37.81% |
| Jun 30, 23 | 759.00 K Increased by +59.45% | -29.69 M Decreased by -14.31% | Decreased by -3.91 K% Increased by +28.31% |
| Mar 31, 23 | 516.00 K Increased by +92.54% | -24.06 M Decreased by -18.11% | Decreased by -4.66 K% Increased by +38.66% |
| Dec 31, 22 | 735.00 K Increased by +410.42% | -30.68 M Decreased by -47.14% | Decreased by -4.17 K% Increased by +71.17% |